PreDxion Bio is an early-stage healthcare company based in South San Francisco that is developing a highly scalable sensor platform (10M+ tests/day) to detect viruses and proteins, with particular emphasis on SARS-CoV-2 and biomarkers (immune markers). PreDxion Bio is backed by Y Combinator, Invest Detroit, and angel investors, and has received funding from the NIH. PreDxion Bio has been granted an FDA Breakthrough Device Designation for the development of our core localized surface plasmon resonance (LSPR) biosensor technology.